PTC Therapeutics Shared Interim Results From Phase 2 PIVOT-HD Study Of PTC518 In Huntington's Disease, Showing Dose-dependent Lowering Of Mutant Huntingtin Protein In Blood/Cerebrospinal Fluid And Favorable Trends On Several Relevant Clinical Assessments
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics shared interim results from its Phase 2 PIVOT-HD study of PTC518 in Huntington's Disease, showing dose-dependent lowering of mutant huntingtin protein in blood/cerebrospinal fluid and favorable trends on several relevant clinical assessments. The FDA has lifted the partial clinical hold on PTC518 based on the PIVOT-HD data.
June 20, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics announced positive interim results from its Phase 2 PIVOT-HD study of PTC518, showing dose-dependent lowering of mutant huntingtin protein and favorable clinical trends. The FDA has lifted the partial clinical hold on PTC518 based on these results.
The positive interim results and the FDA lifting the partial clinical hold are significant milestones for PTC Therapeutics. These developments are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100